Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
13 Results for "
fasting plasma glucose
" in MedChemExpress (MCE) Product Catalog:
Products (13)
13 Results for "fasting plasma glucose" in MCE Product Catalog:
1
1 Cited Publications
Target:
Research Areas:
DBPR108 is an orally active, selective dipeptidyl peptidase-4 (DPP-4) inhibitor with an IC50 of 15 nM. DBPR108 reduces glycated hemoglobin, fasting plasma glucose and postprandial plasma glucose levels, increases serum active GLP-1 and insulin levels, and improves glucose tolerance. DBPR108 can be used in research related to type 2 diabetes .
1
1 Cited Publications
Cat. No.: HY-N0857
CAS No.: 79233-15-1
Cat. No.: HY-P4070
CAS No.: 1188379-43-2
Target:
Research Areas:
Synonyms: GSK189075
Target:
Research Areas:
Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with Ki values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models .
Cat. No.: HY-13414
CAS No.: 329045-45-6
Synonyms: Remogliflozin A
Target:
Research Areas:
Remogliflozin (Remogliflozin A) is an orally active, highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, with a Ki of 12.4 nM for human SGLT2 and 26.0 nM for rat SGLT2. Remogliflozin increases urinary glucose excretion by inhibiting renal glucose reabsorption. Without insulin stimulation, remogliflozin suppresses the elevation of plasma glucose, reduces fasting blood glucose and glycated hemoglobin, and improves glycosuria, hyperglycemia, hyperinsulinemia, hypertriglyceridemia and insulin resistance in diabetic rodents. Remogliflozin can be used in research related to type 2 diabetes .
Cat. No.: HY-122083
CAS No.: 315222-83-4
Target:
Research Areas:
T2384 is a peroxisome proliferator-activated receptor γ (PPARγ) ligand. T2384 also is an orally active antidiabetic agent. T2384 reduces the fasting plasma glucose levels and plasma insulin levels .
Cat. No.: HY-118113
CAS No.: 870710-02-4
BVT-116429 is an 11βHSD1 inhibitor with the activity of increasing adiponectin concentration and improving glucose homeostasis in diabetic mice. BVT-116429 can increase plasma adiponectin levels in diabetic KKAy mice, reduce basal insulin levels, and reduce fasting blood glucose levels after 10 days of inhibition, similar to the effect of rosiglitazone.
Cat. No.: HY-123171
CAS No.: 651055-26-4
Target:
Research Areas:
ASP8497 is a competitive dipeptidyl peptidase IV (DPP-IV) inhibitor that reduces blood glucose levels and increases plasma active GLP-1 and insulin levels without causing hypoglycemia in fasted normal mice. ASP8497 can be utilized for antihyperglycemic research .
Cat. No.: HY-125316
CAS No.: 1138669-65-4
Synonyms: ARRY-403
Target:
Research Areas:
AMG-151 (ARRY-403) is a glucokinase agonist with fasting plasma glucose (FPG) lowering activity. AMG-151 showed a significant linear dose-response trend compared with placebo in a randomized, placebo-controlled Phase IIa study. The use of AMG-151 was associated with a higher incidence of hypoglycemia and hypertriglyceridemia. AMG-151 may serve as a potential compound for the inhibition of type 1 diabetes .
Cat. No.: HY-P992007
Synonyms: RN909
Target:
Research Areas:
Cat. No.: HY-N20390
Target:
Cat. No.: HY-153667
CAS No.: 2101206-49-7
Target:
Research Areas:
MK-2305 is an orally active GPR40 partial agonist with an EC50 of 6 nM in rats. MK-2305 mediates glucose-stimulated insulin secretion and inhibits endogenous glucose production by reducing gluconeogenesis from tricarboxylic acid (TCA) cycle substrates. MK-2305 increases plasma insulin levels under hyperglycemic and glucose-stimulated conditions, reduces fasting blood glucose, and improves glucose homeostasis. MK-2305 can be used in studies related to type 2 diabetes .
Cat. No.: HY-113419
CAS No.: 67605-84-9
Target:
Research Areas:
Cer (d18:1/23:0) is a ceramide (sphingolipid). The level of Cer (d18:1/23:0) increases in coronary heart disease patients exposed to Metformin. The level of Cer (d18:1/23:0) is elevated in Chinese prediabetic and type 2 diabetic patients, and positively correlates with fasting blood glucose levels. Cer (d18:1/23:0) can be used in studies related to coronary heart disease, prediabetes and type 2 diabetes .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
